Eli Lilly & Co. said Wednesday night that its experimental Alzheimer’s treatment did a better job at clearing amyloid plaque than Eisai and Biogen’s Aduhelm in a Phase 3 clinical trial. Amyloid plaque is a biomarker associated with Alzheimer’s. Lilly’s drug, donanemab, reduced amyloid plaque by 37.9%, while Aduhem had plaque clearance of 1.6%. Lilly said the study, which compared the treatments in patients with early symptomatic Alzheimer’s disease, met the primary and secondary endpoints after six months. The ongoing trial is one of five studies that will be used to support the submission to the Food and Drug Administration for approval of donanemab. “We see this disclosure as incrementally positive and await donanemab’s impact on cognition,” SVB Securities analyst David Risinger told investors on Thursday morning. Lilly’s stock is up 34.3% this year, while the broader S&P 500 has declined 14.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
0
0